Vaxcyte, Inc. Common Stock (PCVX)
Vaxcyte, Inc. is a biotechnology company focused on developing next-generation vaccines aimed at preventing infectious diseases. Leveraging its proprietary conjugation platform, Vaxcyte develops innovative vaccines primarily targeting pneumococcal disease, with the goal of providing broader coverage and improved immune responses compared to existing options.
Company News
Thermo Fisher Scientific is issuing a four-part bond offering in the U.S. investment-grade market, with proceeds intended for general corporate purposes amid potential government shutdown concerns.
The pneumococcal infection market is expected to grow steadily, driven by high global disease burden, rising antimicrobial resistance, and expanded immunization initiatives. Over 15 companies are developing 20+ pipeline therapies, with next-generation vaccines targeting broader serotype coverage.
Vaxcyte reported a wider Q2 2025 net loss of $1.22 per share, driven by increased R&D and G&A expenses. The company advanced its VAX-31 vaccine program with FDA Breakthrough Therapy Designation and has $2.8 billion in cash to fund operations through mid-2028.
Does Vaxcyte, Inc. (PCVX) have what it takes to be a top stock pick for momentum investors? Let's find out.